emerg
sever
acut
respiratori
syndrom
sar
result
pandem
spur
flurri
interest
develop
vaccin
prevent
treat
potenti
deadli
viral
infect
research
around
world
pool
scientif
resourc
share
earli
data
unpreced
manner
light
impend
public
health
crisi
still
larg
gap
knowledg
pathogenesi
viru
signific
advanc
made
develop
anim
model
practic
use
may
hamper
lack
patholog
similar
human
diseas
describ
issu
relat
progress
vaccin
develop
obstacl
lie
ahead
research
regulatori
agenc
sever
acut
respiratori
syndrom
sar
first
report
diseas
unknown
etiolog
guangdong
tel
fax
sar
character
fever
cough
flulik
symptom
sever
case
result
alveolar
damag
interstiti
mononuclear
cell
heavi
fibrin
deposit
lung
respiratori
distress
result
atyp
pneumonia
requir
ventil
approxim
patient
aim
review
describ
advanc
made
develop
anim
model
sar
identifi
gap
scientif
understand
need
fill
address
possibl
overcom
challeng
make
use
advanc
made
safe
effect
vaccin
may
attain
inform
may
provid
scientif
basi
facilit
futur
regulatori
decis
relat
licens
sar
vaccin
caus
agent
sar
novel
member
coronaviru
famili
term
sarscov
coronavirus
larg
envelop
rna
virus
name
radiat
spike
protein
found
surfac
virion
fig
three
group
relat
coronavirus
sar
may
member
new
fourth
group
classif
sar
coronaviru
controversi
although
phylogenet
similar
may
place
viru
subgroup
group
coronavirus
human
coronavirus
includ
three
member
caus
common
respiratori
infect
nonhuman
coronavirus
includ
caus
respiratori
infect
bird
enter
infect
cattl
pig
dog
cat
virus
affect
multipl
organ
exampl
mous
hepat
viru
mhv
felin
infecti
periton
fip
viru
capabl
caus
respiratori
enter
neurolog
hepat
infect
coronavirus
positivesens
rna
virus
replic
uniqu
mechan
wherebi
structur
gene
express
nest
set
subgenom
mrna
character
share
common
end
conserv
cap
leader
sequenc
nonstructur
gene
transcrib
end
polyprotein
process
viral
proteas
fig
protein
translat
open
read
frame
mrna
sar
cov
eight
open
read
frame
unknown
function
structur
protein
found
coronavirus
includ
envelop
e
matrix
membran
protein
spike
nucleocapsid
n
protein
glycosyl
requir
viral
attach
possibl
entri
nucleocapsid
protein
coat
viral
genom
rna
virus
belong
group
mhv
also
contain
hemagglutininesteras
protein
present
group
flulik
symptom
atyp
pneumonia
characterist
sarscov
infect
also
frequent
accompani
lymphopenia
alveolar
macrophag
preval
patient
fatal
sar
contribut
immunemedi
natur
diseas
situ
hybrid
show
viral
infect
present
alveolar
epitheli
cell
viral
rna
could
also
detect
structur
gene
spike
envelop
membran
nucleocapsid
locat
end
includ
mani
eight
gene
unknown
function
alveolar
macrophag
bronchiolar
epitheli
cell
sever
studi
suggest
immun
system
may
impair
sar
cov
tcell
lymphopenia
observ
patient
observ
declin
cell
type
two
week
diseas
onset
cellmedi
immun
inflammatori
respons
note
mark
elev
cytokin
ifn
gamma
neutrophil
chemokin
tnf
accumul
monocytesmacrophag
neutrophil
also
observ
li
et
al
note
rapid
declin
tcell
subset
peripheri
observ
patient
acut
phase
sar
infect
observ
restor
cell
recoveri
presenc
proinflammatori
cytokin
may
result
activ
alveolar
macrophag
suggest
may
play
role
pathogenesi
sar
antibodi
sar
coronaviru
found
retrospect
sampl
collect
indic
outbreak
first
time
sar
enter
human
popul
infect
patient
develop
humor
respons
sarscov
antivir
antibodi
igg
igm
detect
day
postonset
symptom
igm
antibodi
declin
day
igg
antibodi
persist
day
antivir
neutral
antibodi
obtain
convalesc
patient
morbid
rate
greater
older
individu
children
year
age
develop
sever
diseas
seen
adult
taken
togeth
data
may
suggest
qualiti
immun
respons
may
play
role
outcom
viru
infect
addit
challeng
relat
contain
sarscov
lack
identif
natur
host
viru
detect
wild
domest
anim
first
peopl
infect
anim
handler
food
market
guangdong
provinc
china
suggest
role
zoonot
transmiss
sar
strain
observ
anim
vari
slightli
human
viru
may
repres
recent
jump
across
speci
develop
good
anim
model
use
identifi
natur
host
invalu
determin
correl
immun
test
therapeut
vaccin
develop
remark
advanc
sar
research
came
discoveri
mice
suscept
infect
sarscov
balbc
mice
infect
tissu
cultur
infect
dose
tcid
day
infect
yield
tcid
per
gram
respect
lung
tissu
although
clinic
diseas
observ
mild
focal
peribronchiolar
mononuclear
inflammatori
infiltr
observ
upon
microscop
examin
respiratori
tract
day
infect
presenc
infiltr
may
suggest
mimicri
human
clinic
featur
although
much
milder
respiratori
tract
mice
clear
viru
day
infect
wentworth
et
al
found
sarscov
stomach
intestin
duodenum
addit
respiratori
tract
infect
mice
subbarao
et
al
also
protect
mice
infect
passiv
administr
sarscov
neutral
antibodi
previous
infect
mice
suggest
neutral
vivo
possibl
mice
clear
viru
day
postinfect
human
begin
clear
infect
day
small
anim
model
allow
research
test
therapeut
vaccin
mice
recov
viru
infect
effici
also
identifi
host
factor
contribut
viru
resolut
hamster
also
shown
good
model
sarscov
infect
reach
similar
titer
seen
mice
surprisingli
immunodefici
mice
clear
sarscov
infect
mice
background
lack
nkt
cell
nk
cell
beig
lack
b
cell
ragl
clear
viru
day
infect
mice
display
high
induct
proinflammatori
cytokin
suggest
adapt
immun
respons
nk
cell
requir
viral
clearanc
mice
furthermor
indic
involv
innat
immun
respons
import
control
viru
interest
specul
interferon
pathway
may
import
viral
clearanc
evid
import
innat
immun
provid
infect
mice
sarscov
import
regul
interferon
mice
produc
two
log
increas
viral
titer
control
mice
addit
mutant
mice
develop
interstiti
pneumonia
seen
control
mice
alveolar
damag
seen
lung
human
patient
unclear
time
observ
patholog
differ
human
mous
lung
due
time
sampl
differ
host
respons
domest
cat
ferret
also
test
use
sarscov
anim
model
cat
ferret
inocul
tcid
sarscov
cat
show
clinic
symptom
three
six
ferret
becam
letharg
one
die
viru
recov
lung
infect
cat
tcid
gram
tissu
ferret
tcid
gram
tissu
experi
also
show
horizont
transmiss
viru
may
occur
cat
hous
togeth
ferret
hous
togeth
although
kinet
mode
transmiss
still
unknown
noninocul
infect
ferret
becam
letharg
develop
conjunct
die
day
postinfect
ferret
show
evid
pneumonia
exhibit
hepat
lipidosi
emaci
ter
meulen
et
al
show
ferret
infect
sarscov
show
sign
multifoc
pulmonari
lesion
affect
lung
alveolar
damag
lymphocyt
infiltr
also
observ
upon
histolog
examin
infect
ferret
lung
tissu
three
speci
monkey
test
infect
sarscov
cynomolgu
rhesu
african
green
african
green
monkey
support
highest
level
viral
replic
yield
viral
titer
approxim
tcid
ml
nasal
swab
research
work
cynomolgu
macaqu
report
sign
diseas
resembl
sar
monkey
infect
sarscov
day
postinfect
macaqu
becam
letharg
temporari
skin
rash
one
anim
show
sign
respiratori
distress
two
macaqu
interstiti
pneumonia
lesion
present
similar
autopsi
tissu
obtain
sar
patient
group
report
cynomolg
macaqu
show
limit
patholog
mild
diseas
upper
respiratori
symptom
appar
explan
discrep
group
possibl
viru
strain
differ
monkey
subspeci
differ
may
account
differ
outcom
conclud
nonhuman
primat
similarli
mimic
human
diseas
still
controversi
vaccin
efficaci
measur
abil
antigen
rais
protect
immunolog
respons
b
cell
exposur
viral
agent
ideal
creat
memori
within
immun
system
individu
protect
infect
decad
sever
veterinari
coronaviru
vaccin
current
avail
efficaci
variabl
vaccin
prevent
infecti
bronchiti
viru
ibv
infect
chicken
effect
canin
porcin
vaccin
partial
effect
felin
infecti
periton
fip
vaccin
actual
deleteri
health
anim
discuss
detail
vaccin
produc
inactiv
viru
use
attenu
weak
form
viru
use
recombin
form
viral
compon
inactiv
viru
vaccin
rel
safe
revert
back
live
form
also
rel
stabl
may
even
requir
refriger
import
develop
countri
eas
mobil
outbreak
emerg
situat
howev
limit
use
inactiv
vaccin
usual
requir
sever
dose
weakli
effect
stimul
immun
respons
vaccin
prevent
hepat
exampl
inactiv
viral
vaccin
live
attenu
viral
vaccin
may
requir
special
laboratori
develop
alway
obtain
reach
effect
level
viru
must
capabl
robust
replic
must
lost
abil
caus
diseas
sever
problem
associ
use
live
attenu
vaccin
vaccin
must
kept
refriger
frozen
safeti
issu
relat
possibl
revers
wildtyp
form
addit
almost
never
given
immunocompromis
individu
fear
attenu
form
may
caus
diseas
absenc
effect
immun
respons
recombin
dna
viral
vector
construct
lab
use
potenti
vaccin
studi
tissu
tropism
sar
viru
vector
use
deliv
foreign
antigen
use
attenu
nonpathogen
organ
safeti
type
vaccin
center
around
persist
express
vivo
possibl
genom
integr
foreign
dna
possibl
evolutionari
chang
may
caus
instabl
viral
vector
potenti
transmiss
viral
vector
includ
introduct
environ
also
evalu
ideal
recombin
vaccin
might
engin
includ
inher
abil
foreign
substanc
clear
drug
treatment
proven
safe
antibiot
antibiot
sensit
introduc
recombin
vector
may
allay
fear
futur
advers
event
although
design
may
rais
addit
safeti
concern
recombin
protein
also
use
stimul
immun
respons
protein
purifi
yeast
bacteria
current
use
manufactur
licens
hepat
b
vaccin
cell
substrat
use
manufactur
vaccin
also
concern
vaccin
product
must
perform
wellcharacter
cell
substrat
vero
cell
use
produc
licens
polioviru
vaccin
may
appropri
use
develop
sar
vaccin
sar
grow
well
vero
cell
fda
center
biolog
evalu
research
cber
issu
letter
sponsor
use
vero
cell
cell
substrat
investig
vaccin
found
cber
websit
anoth
consider
use
fetal
bovin
serum
bovin
deriv
growth
cell
bovin
tissu
may
contain
bovin
spongiform
enceph
bse
agent
guidelin
use
bsefre
blood
product
appear
fda
websit
guidelin
use
bsefre
bovin
deriv
product
vaccin
virus
variabl
strain
combin
vaccin
may
effect
combin
vaccin
one
consist
two
live
organ
inactiv
organ
purifi
antigen
combin
type
vaccin
may
use
prevent
multipl
organ
strain
organ
compon
must
make
contribut
whole
compat
compon
necessari
rna
virus
replic
rnadepend
rna
polymeras
encod
viru
type
polymeras
proofread
mechan
associ
result
high
rate
uncorrect
mutat
mutat
may
may
lethal
viru
replic
may
even
persist
result
rapid
evolut
viru
reason
mani
rna
virus
multipl
genom
strain
quasispeci
present
one
time
individu
quasispeci
may
aris
respons
select
immun
pressur
thu
allow
escap
mutant
exist
quasispeci
sarscov
infect
come
light
import
escap
immun
surveil
still
unknown
coronavirus
thought
abil
recombin
due
homolog
sequenc
end
mrna
evid
suggest
sarscov
origin
recombin
coronavirus
addit
hostspeci
drift
larg
small
anim
infect
sarscov
giant
advanc
vaccin
research
examin
infect
anim
model
provid
inform
lead
understand
correl
immun
mice
use
understand
viru
neutral
cytokin
upregul
minimum
requir
viral
clearanc
yet
show
diseas
mimic
atyp
pneumonia
seen
adult
human
report
diseas
cynomolg
macaqu
mani
group
reproduc
find
promis
anim
model
may
domest
ferret
ferret
show
elev
liver
enzym
lymphocyt
infiltr
alveolar
damag
also
observ
human
despit
use
anim
model
mani
challeng
lie
ahead
first
anim
model
sarscov
infect
mimic
human
diseas
mice
viru
clear
less
week
minor
patholog
lung
observ
histopatholog
perform
necropsi
sampl
suggest
lung
epitheli
cell
involv
although
absenc
pneumonia
infiltr
macrophag
disappoint
mice
may
prove
promis
anim
model
similarli
mimic
human
diseas
second
order
test
efficaci
larg
human
popul
must
test
area
viru
endem
final
sar
fail
return
vaccin
manufactur
test
candid
vaccin
efficaci
anim
rule
provid
type
case
anim
model
mimic
human
diseas
order
applic
final
rule
publish
feder
regist
found
feder
regist
websit
addit
coronavirus
may
induc
shortliv
immun
may
reason
human
subject
multipl
infect
coronavirus
caus
common
cold
longterm
immun
studi
sarscov
current
underway
antibodydepend
enhanc
ade
observ
vaccin
wildtyp
infect
fip
ade
thought
potenti
viral
infect
infect
macrophag
viral
entri
macrophag
occur
antibodi
bind
viru
attach
macrophag
via
fc
region
antibodi
interact
cell
surfac
express
fc
receptor
neutral
antibodi
also
enhanc
antibodi
antibodi
titer
low
igg
class
macrophag
increas
viral
diseas
cell
type
may
provid
abund
reservoir
viru
thu
expans
viru
host
similar
fip
sar
exist
first
case
macrophag
infect
viru
case
sar
etiolog
diseas
contribut
infiltr
alveolar
macrophag
lead
pneumon
second
treatment
corticosteroid
andor
interferon
alpha
amelior
sar
diseas
suggest
inflammatori
immunemedi
diseas
observ
ade
sar
infect
worth
note
one
coronaviru
fipv
capabl
elicit
ade
evalu
vaccin
may
want
consid
possibl
outcom
howev
difficulti
test
anim
model
ade
bear
caveat
ade
observ
prove
vaccin
safe
regard
ade
human
contrast
anim
model
ade
develop
may
learn
mechan
sarsinduc
ade
may
help
form
basi
develop
guidelin
safe
vaccin
develop
potenti
sar
vaccin
might
target
viru
specif
humor
cellmedi
immun
respons
altern
therapeut
vaccin
may
use
treatment
viral
infect
spikespecif
monoclon
polyclon
antibodi
neutral
viru
develop
passiv
transfer
immun
serum
naiv
mice
protect
infect
sarscov
suggest
neutral
antibodi
alon
prevent
viral
infect
neutral
may
requir
host
recognit
fc
region
antibodi
need
develop
human
form
type
antibodi
may
critic
consid
use
treatment
human
monoclon
antibodi
deriv
phage
display
librari
administ
ferret
protect
ferret
lung
diseas
shed
viru
pharyng
secret
neutral
antibodi
convalesc
patient
identifi
character
usual
neutral
epitop
locat
spike
protein
viru
recent
evid
determin
viru
neutral
sensit
deglycosyl
spike
protein
suggest
conform
epitop
import
antibodi
recognit
sarscov
effici
inactiv
ultraviolet
uv
irradi
mice
immun
uvinactiv
sarscov
develop
humor
cellmedi
immun
respons
cell
prolifer
cytokin
upregul
observ
boost
inactiv
viru
betapropiolactoneinactiv
viru
also
elicit
neutral
antibodi
administ
balbc
mice
formalininactiv
sarscov
yield
potent
humor
respons
balbc
mice
well
recombin
virus
may
use
elicit
respons
introduc
sarscov
gene
first
type
recombin
viru
defect
nonpathogen
vector
express
sarscov
protein
second
type
one
stimul
assembl
viruslik
particl
vlp
vitro
vlp
contain
structur
envelop
protein
includ
spike
envelop
e
membran
protein
assembl
coinfect
insect
cell
three
baculovirus
express
one
three
structur
protein
structur
protein
express
live
attenu
bovin
parainfluenza
viru
type
evalu
efficaci
hamster
african
green
monkey
high
titer
neutral
antibodi
obtain
one
intranas
immun
vector
singl
immun
express
alon
provid
complet
protect
upon
challeng
sarscov
recombin
live
attenu
modifi
vaccinia
viru
ankara
mva
use
deliv
sar
spike
protein
rmva
balbc
mice
neutral
antibodi
obtain
reduct
viral
titer
observ
challeng
live
sarscov
ferret
challeng
sarscov
vaccin
rmva
show
enhanc
liver
diseas
demonstr
increas
alt
valu
presenc
mononuclear
hepat
upon
histolog
examin
data
suggest
enhanc
diseas
due
vaccin
sar
protein
adenovirus
express
n
protein
use
combin
vaccin
rhesu
macaqu
immun
anim
antibodi
respons
protein
tcell
respons
n
protein
highli
infecti
hiv
particl
express
protein
made
primarili
studi
hostcel
distribut
put
sarscov
receptor
addit
investig
requir
viral
receptor
bind
entri
also
enhanc
understand
requir
viral
control
recombin
hiv
particl
express
sar
spike
protein
may
provid
insight
cell
tropism
receptor
express
profil
anoth
retroviru
murin
leukemia
viru
use
gener
infecti
particl
contain
protein
convalesc
serum
abl
neutral
infect
recombin
viru
vero
cell
high
cytotox
tlymphocyt
ctl
antibodi
respons
observ
mice
inject
three
time
recombin
plasmid
vector
express
n
protein
mice
immun
plasmid
contain
protein
produc
antisarscov
igg
develop
neutral
antibodi
tcell
mediat
respons
result
sixfold
reduct
viral
titer
lung
plasmid
encod
either
region
spike
protein
elicit
antibodi
product
mice
neither
antibodi
alon
capabl
neutral
viru
howev
cooper
enabl
neutral
viru
suggest
region
spike
protein
import
hostcel
viral
entri
nucleocapsid
protein
may
also
stimul
effect
immun
respons
dna
vaccin
calreticulin
fuse
n
protein
gener
sarsspecif
humor
cellular
immun
mice
calreticulin
use
found
enhanc
major
histocompat
complex
class
present
fusion
protein
cell
recombin
virus
may
gener
fulllength
infecti
cdna
clone
sarscov
clone
may
provid
sourc
genet
manipul
genom
viral
virul
factor
understood
attenu
strain
may
obtain
engin
mutat
viru
vaccin
develop
may
proceed
undertak
systemat
approach
understand
correl
immun
rais
sarscov
much
focu
center
toward
humor
respons
neutral
epitop
cellmedi
immun
may
also
import
ctl
epitop
within
sarscov
may
present
human
leukocyt
antigen
supertyp
identifi
advanc
bioinformat
character
epitop
includ
recognit
convalesc
serum
advanc
understand
import
immunolog
featur
control
sarscov
intens
studi
sar
still
much
unknown
patholog
viru
mani
research
question
need
answer
thu
provid
resourc
necessari
develop
effect
safe
vaccin
sure
vaccin
provid
coverag
potenti
variabl
viru
need
know
occurr
viral
quasispeci
variabl
import
epitop
viral
virul
factor
use
inform
develop
attenu
strain
viru
establish
persist
infect
human
repeatedli
infect
also
need
determin
innat
humor
cellmedi
immun
respons
recov
sar
patient
order
understand
viral
clearanc
come
understand
viral
pathogenesi
must
know
immun
system
mediat
diseas
role
lymphocyt
infiltr
alveolar
macrophag
enhanc
diseas
control
infect
defin
abil
viru
replic
monocytesmacrophag
assur
antibodydepend
enhanc
problem
sar
vaccin
importantli
identif
natur
anim
host
may
launch
develop
larg
small
anim
model
correl
immun
drug
vaccin
screen
develop
anim
model
mimic
human
diseas
singl
import
advanc
develop
sar
vaccin
develop
vaccin
sarscov
imper
research
head
forward
direct
enabl
public
health
commun
readi
